HIV Scientific Papers
Tesamorelin, a growth hormone-releasing factor analogue, improves inflammatory markers in HIV-infected patients with excess abdominal fat: relationships between changes in inflammatory markers and changes in visceral adipose tissue (VAT) [abstract].
2010
Antiviral Therapy
Mamputu J-C, Falutz J, Pham MH, et al.
15(suppl 4):A6. Proceedings of the 12th International Workshop on Adverse Drug Reactions and Co-Morbidities.
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extens ...
2010
J Clin Endocrinol Metab.
Falutz J, Mamputu J-C, Potvin D, et al.
95(9):4291-4304.
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
2010
J Acquir Immune Defic Syndr.
Falutz J, Potvin D, Mamputu J-C, et al.
53(3):311-322.
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
2009
Antimicrob Agents Chemother.
Jacobson JM, Kuritzkes DR, Godofsky E, et al.
53(2):450-457.
Pharmacokinetic/pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone releasing factor (GRF) analog, administered subcutaneously once daily for 14 consecutive days in healthy and HIV positive populations.
2009
Michaud S-E, Abolfathi Z, Potvin D, et al.
"Poster #P3-641 presented at: ENDO; June 10-13, 2009; Washington, DC, USA.
"